ProCE Banner Activity

ELM-2: Final Analysis From Phase II Trial of Odronextamab in Relapsed/Refractory DLBCL

Conference Coverage

In the final analysis of this pivotal phase II trial, odronextamab achieved an ORR of 52% and CR of 31%, with a manageable safety profile, in patients with heavily pretreated relapsed/refractory diffuse large B-cell lymphoma.

Released: December 14, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.